Clostridioides difficile Toxin B Specific Neutra™ Antibody Products

Are prolonged drug development timelines or challenges in neutralizing C. difficile toxin B hindering your progress? Creative Biolabs' C. difficile toxin B specific Neutra™ antibody products leverage advanced hybridoma screening and epitope-specific engineering to deliver high-affinity, toxin-neutralizing antibodies. Streamline your therapeutic development with reagents validated for robust specificity and functional efficacy in complex biological models.

Introduction to C. difficile Toxin B

Clostridioides difficile (C. difficile) toxin B is a large, single-subunit exotoxin (308 kDa) produced by the opportunistic pathogen C. difficile. It acts as a primary virulence factor in antibiotic-associated diarrhea and pseudomembranous colitis. Toxin B disrupts host cell cytoskeletal integrity by catalyzing the glucosylation of Rho GTPases, leading to cell rounding, inflammation, and tissue necrosis.

• Structural Insights

C. difficile toxin B comprises four functional domains:

1. The N-terminal glucosyltransferase domain (GTD), which modifies Rho GTPases.

2. The cysteine protease domain facilitating auto-cleavage for toxin activation.

3. The central hydrophobic region involved in pore formation during endosomal escape.

4. The C-terminal combined repetitive oligopeptide (CROPs) domain mediating host cell receptor binding. Recent cryo-EM studies reveal that the CROPs domain adopts a β-solenoid fold, enabling dynamic interactions with cell-surface carbohydrates like chondroitin sulfate.

• Associated Signaling Pathways

Toxin B binds to host cell receptors via its CROPs domain, triggering clathrin-mediated endocytosis. Acidification of endosomes induces conformational changes, promoting pore formation and GTD translocation into the cytoplasm. Glucosylation of Rho GTPases (RhoA, Rac1, Cdc42) inhibits their ability to regulate actin polymerization, resulting in apoptosis, barrier dysfunction, and inflammatory cytokine release (e.g., IL-8, TNF-α).

• Disease Relevance

C. difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, with recurrent cases linked to toxin-mediated damage. Severe CDI progresses to colonic perforation, sepsis, or toxic megacolon, underscoring the need for toxin-targeted therapies.

Fig. 1 C. difficile toxin B structure and action.¹

Applications of Anti-C. difficile Toxin B Antibodies

• Diagnostic Assay Development

The antibodies enable precise detection of toxin B in stool samples via lateral flow assays or ELISA. High specificity minimizes cross-reactivity with nonpathogenic C. difficile strains, improving diagnostic accuracy for early-stage CDI.

• Therapeutic Candidate Screening

Evaluate toxin-neutralizing efficacy in in vitro models using human colonic organoids or T84 cell monolayers. Antibodies precluding Rho GTPase glucosylation restore epithelial barrier function, serving as critical benchmarks for drug development.

• Mechanistic Studies of Toxin Biology

Map toxin-host interactions via co-immunoprecipitation or surface plasmon resonance (SPR). Antibodies targeting the GTD or CROPs domain elucidate structural determinants of toxicity, informing rational vaccine design.

• Passive Immunotherapy Development

Prophylactic or therapeutic administration of neutralizing antibodies reduces colonic inflammation and bacterial colonization in preclinical models.

Our Neutralizing Antibodies Against C. difficile Toxin B

Creative Biolabs offer anti-toxin B antibody products which are engineered to inhibit toxin-receptor binding or glucosyltransferase activity. Our antibody categories include:

- Recombinant antibodies targeting the CROPs domain, blocking host cell adhesion.

- Neutralizing antibodies against the GTD, preventing Rho GTPase inactivation.

- Biparatopic antibodies that cross-link toxin monomers, enhancing neutralization potency.

Validated in vitro cytotoxicity assays and in vivo mouse CDI models, these antibodies exhibit greater than 90% toxin-neutralizing efficacy at picomolar concentrations. Compatibility with ELISA, Immunohistochemistry, and flow cytometry ensures versatility in research and diagnostic workflows.

Fig. 2 Workflow of Recombinant Anti-C. difficile Toxin B Antibody Production.

Creative Biolabs delivers rigorously validated C. difficile toxin B specific neutra™ antibodies to accelerate your CDI research and therapeutic programs. Our antibodies combine unmatched specificity, functional potency, and scalability to meet translational demands. Contact us today to discuss customized solutions for your project.

REFERENCE

1. Aktories, Klaus. "From signal transduction to protein toxins—a narrative review about milestones on the research route of C. difficile toxins." Naunyn-schmiedeberg's Archives of Pharmacology 396.2 (2023): 173-190. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1007/s00210-022-02300-9